首页> 外文期刊>Journal of diabetes and its complications >Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes
【24h】

Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes

机译:exenatide治疗增加肥胖患者的血清Iriisin水平和新诊断的2型糖尿病

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: Irisin is a myokine secreted by skeletal muscle during exercise. Abnormal serum irisin levels are associated with obesity and type 2 diabetes (T2D). This study investigated the changes in serum irisin in the obese patients with newly diagnosed T2D following glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide) treatment.
机译:目的:Irisin是在运动期间被骨骼肌分泌的肌肌。 异常血清赤素水平与肥胖和2型糖尿病(T2D)有关。 本研究调查了在胰高血糖素肽-1(GLP-1)受体激动剂(Exenatide)处理后新诊断的T2D患者血清伊森松的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号